key: cord-0729550-bssv3o4l authors: Dal‐Ré, Rafael title: Clinical Equipoise in COVID‐19 Vaccine Candidates Trials date: 2021-04-07 journal: J Clin Pharmacol DOI: 10.1002/jcph.1868 sha: d6aae1ed8ae2a5e254322398df364b0fb955fd17 doc_id: 729550 cord_uid: bssv3o4l nan This article is protected by copyright. All rights reserved. To be ethically acceptable, any randomized controlled trial (RCT) must comply with the clinical equipoise principle. This principle holds when the medical community does not know which of the interventions under study is therapeutically superior. 1 Clinical equipoise exits when there is a truly uncertainty about the merits of the interventions, so no participant in the RCT will receive a known inferior intervention. If the uncertainty disappears, the RCT is no longer ethically acceptable and must then be terminated: trial participants should then have access to the intervention that has been shown to be superior. When dealing with placebocontrolled RCTs, the intervention that has shown to be superior refers both to the one that is being assessed in a given RCT or in another RCT. to preventing COVID-19 symptoms in the short term ─the viewpoint shared by trial participants. However, they argued that uncertainty is still present with regard to other outcomes such as infectivity of vaccine recipients, and the long-term efficacy and safety of vaccines ─the viewpoint of some scientists and regulators. They end their argument 10 by stating that a detailed analysis should be conducted for these cases in which uncertainty still exists, something that will help to explain the opposing viewpoints of trial participants and some scientists regarding the voluntary withdrawal of participants when a COVID-19 vaccine is available. The detailed analysis proposed, 10 although important from the theoretical standpoint, has no practical relevance. To address the three outcomes mentioned above, investigators must ensure the presence of clinical equipoise the moment the first COVID-19 authorized vaccine becomes available to trial participants ─regardless of the uncertainties the medical community might have in the long-term. The absence of uncertainty in the short term takes precedence over any other consideration ─irrespective of its scientific importance. Infectivity of vaccine recipients and long-term efficacy and safety data should be scientifically addressed with other types of studies, such as the rolling cross-over design (double-blind or open-label) that could be conducted once placebo recipients are vaccinated with the authorized vaccine assessed in the RCT (7, 11) or by conducting long-term observational studies (e.g., cohort studies). Finally, it should be highlighted that all the above is applicable to the recently started placebo-controlled RCTs assessing COVID-19 vaccine candidates in pediatrics. This article is protected by copyright. All rights reserved. Equipoise and the ethics if clinical research Ethical and Scientific Considerations Regarding the Early Approval and Deployment of a COVID-19 Vaccine Emergency use authorization of COVID vaccines ─ safety and efficacy follow-up considerations Ad Hoc Expert Group on the Next Steps for COVID-19 Vaccine Evaluation Trials of COVID-19 Vaccines -Why We Still Need Them The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials Online ahead of print Trial participants' right after authorization of COVID-19 vaccines US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine COVID-19 vaccine trial participants. An open letter from COVID-19 vaccine trial participants COVID-19 vaccines research and the trouble with clinical equipoise Evaluating the Long-Term Efficacy of COVID